Financial Information
We introduce ADBIOTECH’s technology intended to replace vaccines
and antibiotics.
(Unit: KRW in millions)
Sales
Operating profit
Net profit
Income Statements(Unit: KRW in millions)
| Item | 2021 | 2022 | 2023 |
|---|---|---|---|
| Operating profit | -1,483 | -4,779 | -2,580 |
| Other gains | 2 | 1 | 2 |
| Other losses | 96 | 284 | 2,882 |
| Finance costs | 957 | 1,656 | 1,955 |
| Finance income | 189 | 9,404 | 4,962 |
| Cost Of Sales | 4,927 | 3,096 | 2,967 |
| Net profit | -2,594 | 2,686 | -2,454 |
| Sales | 11,712 | 10,650 | 8,493 |
(Unit: KRW in millions)
Total Assets
Total liabilities
Total equity
Financial Position(Unit: KRW in millions)
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Total Assets | 21,124 | 30,993 | 27,703 |
| Current Assets | 8,679 | 13,859 | 14,445 |
| Non-current Assets | 12,445 | 17,134 | 13,258 |
| Capital surplus | 18,293 | 27,257 | 27,257 |
| Total equity | 5,242 | 16,324 | 13,932 |
| Share capital | 3,847 | 4,570 | 4,570 |
| Retained earnings | -16,128 | -13,442 | -15,896 |
| Current liabilities | 12,654 | 11,629 | 10,238 |
| Total liabilities | 15,882 | 14,669 | 13,771 |
| Non-Current liabilities | 3,228 | 3,040 | 3,533 |